Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.64 |
| ▸ | EHMT2 | Q96KQ7 | 10/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284994 | 0.87 | EHMT2 (0.70) | MAPTPOLBTHRBEHMT2MEN1 | |
| SCHEMBL13284988 | 0.84 | EHMT2 (0.68) | MAPTPOLBTHRBEHMT2MEN1 | |
| SCHEMBL13284978 | 0.84 | MEN1 (0.65) | MAPTTP53POLBTHRBEHMT2 | |
| SCHEMBL15944919 | 0.84 | MAPT (1.00) | MAPTTP53POLBTHRBNTRK1 | |
| SCHEMBL15940264 | 0.83 | MAPT (0.81) | MAPTTP53POLBTHRBNTRK1 | |
| SCHEMBL13285002 | 0.82 | MAPT (1.00) | MAPTTP53POLBTHRBNTRK1 | |
| SCHEMBL13284983 | 0.81 | MAPT (0.85) | MAPTTP53POLBTHRBNTRK1 | |
| SCHEMBL16978025 | 0.81 | MAPT (0.87) | MAPTTP53POLBTHRBNTRK1 | |
| SCHEMBL16978027 | 0.80 | NTRK1 (0.81) | MAPTTP53POLBTHRBNTRK1 | |
| SCHEMBL13284987 | 0.78 | NTRK1 (1.00) | MAPTTP53POLBTHRBNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301133-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2011-12-08 | — | — | US | claimed |
| US-10421763-B2 | Compositions of protein receptor tyrosine kinase inhibitors | PURDUE PHARMA L.P. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421763-B2 | Compositions of protein receptor tyrosine kinase inhibitors | PURDUE PHARMA L.P. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180086777-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | PURDUE PHARMA L.P. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086777-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | PURDUE PHARMA L.P. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9738659-B2 | Compositions of protein receptor tyrosine kinase inhibitors | PURDUE PHARMA L.P. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738659-B2 | Compositions of protein receptor tyrosine kinase inhibitors | PURDUE PHARMA L.P. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738659-B2 | Compositions of protein receptor tyrosine kinase inhibitors | PURDUE PHARMA L.P. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150218188-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218188-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-8809530-B1 | Compositions of protein receptor tyrosine kinase inhibitors | VM PHARMA LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809530-B1 | Compositions of protein receptor tyrosine kinase inhibitors | VM PHARMA LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809530-B1 | Compositions of protein receptor tyrosine kinase inhibitors | VM PHARMA LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140228331-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | PURDUE PHARMA L.P. | 2014-08-14 | — | — | US | disclosed |
| US-20140228331-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | PURDUE PHARMA L.P. | 2014-08-14 | — | — | US | disclosed |
| US-20140228331-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | PURDUE PHARMA L.P. | 2014-08-14 | — | — | US | disclosed |
| US-20110301133-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301133-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301133-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010077680-A2 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM DISCOVERY INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218188-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | NGFR, NGF, GRB2 | MAPT 576/4885TP53 958/4885POLB 2373/4885 |
| US-10421763-B2 | Compositions of protein receptor tyrosine kinase inhibitors | NGFR, NGF, GRB2 | MAPT 576/4885TP53 958/4885POLB 2373/4885 |
| US-20140228331-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | NGFR, NGF, GRB2 | MAPT 576/4885TP53 958/4885POLB 2373/4885 |
| US-20180086777-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | NGFR, NGF, GRB2 | MAPT 536/4885TP53 916/4885POLB 2441/4885 |
| US-20110301133-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | NGFR, NGF, GRB2 | MAPT 576/4885TP53 958/4885POLB 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.